PT Itama Ranoraya TbkISX:IRRA +2.25%81 ROE % is 7.33% as of Mar. 2026, which is 57% below its 10-year median of 17.01. GuruFocus rates ISX:IRRA with a GF Score™ of 81/100 and a GF Value™ of Rp534.14 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 113 Medical Distribution companies, PT Itama Ranoraya Tbk ranks better than 70.8% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, PT Itama Ranoraya Tbk's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Itama Ranoraya Tbk ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Itama Ranoraya Tbk's ROE % distribution charts can be found below:
* The bar in red indicates where PT Itama Ranoraya Tbk's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
PT Itama Ranoraya Tbk (ISX:IRRA) has a ROE % of 7.33% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Itama Ranoraya Tbk and its competitors. This is 57% below median its historical median of 17.01. Over the past decade, PT Itama Ranoraya Tbk's ROE % has ranged from 1.10 to 86.98. According to the industry distribution chart, PT Itama Ranoraya Tbk ranks #33 out of 113 companies in the Medical Distribution industry, placing it in the top 29.2%.
Is PT Itama Ranoraya Tbk's ROE % too high?
PT Itama Ranoraya Tbk's current ROE % of 7.33% is 57% below median its 10-year median of 17.01. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 86.98. The Medical Distribution industry median ROE % is 7.10. PT Itama Ranoraya Tbk's value of 7.33% is 3.2% above this industry median. Based on the distribution chart, PT Itama Ranoraya Tbk ranks #33 out of 113 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Itama Ranoraya Tbk has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Itama Ranoraya Tbk's ROE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, PT Itama Ranoraya Tbk ranks #33 out of 113 companies for ROE %. This puts PT Itama Ranoraya Tbk in the upper half of its industry. The industry median ROE % is 7.10. PT Itama Ranoraya Tbk's value of 7.33% is 3.2% above this benchmark. Historically, PT Itama Ranoraya Tbk's own ROE % has ranged from 1.10 to 86.98 over the past decade. While the company's 10-year median is 17.01 vs. the industry median of 7.10, PT Itama Ranoraya Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Itama Ranoraya Tbk's current ROE % of 7.33% is 3.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Itama Ranoraya Tbk and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Itama Ranoraya Tbk's current ROE % is 7.33%, which is 57% below median its own 10-year median of 17.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Itama Ranoraya Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk (ISX:IRRA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp534.14, compared to a current price of Rp364.00 — trading 31.9% below its estimated fair value. The current ROE % is 7.33%, which is 57% below median its 10-year median of 17.01 and 3.2% above the Medical Distribution industry median of 7.10. PT Itama Ranoraya Tbk's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For PT Itama Ranoraya Tbk (ISX:IRRA), the current ROE % is 7.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Itama Ranoraya Tbk (ISX:IRRA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Itama Ranoraya Tbk stock appears to be undervalued.
The current stock price of Rp364.00 is trading 31.9% below its estimated GF Value™ of Rp534.14.
GuruFocus considers PT Itama Ranoraya Tbk to be Possible Value Trap.
Key valuation signals for ISX:IRRA:
ROE %: 7.33% (57% below median its 10-year median of 17.01)
GF Value™: Rp534.14 vs. price of Rp364.00 (31.9% below fair value)
Industry Position: 3.2% above the Medical Distribution median (#33 of 113)
No single metric tells the full story. See the ISX:IRRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Itama Ranoraya Tbk focuses on the trade and distribution of medical devices. The company distributes medical devices such as Oneject auto disable syringe, Abbott diagnostics, TerumoBCT, Ortho Clinical diagnostics and others. It business segment includes Vitro Diagnostic Products, Non-Electromedical Sterile Medical Devices, Electromedical Sterile Medical Devices and Other Segments. The key revenue generating segments of the company are In Vitro Diagnostic product.
81GF Score
Get the complete analysis for ISX:IRRA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:IRRA has been successfully added to your 
